RxDoctor Payments Data

Michael Mason, OD

Optometrist · Hazlehurst, GANPI 1982686564

Payments from drug & device makers

$746in general payments, 2019–2025

Across 30 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$423
  • Rxsight Inc$150
  • Sun Pharmaceutical Industries Inc.$80
  • Johnson & Johnson Surgical Vision, Inc.$38
  • Optos, Inc.$30
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$24

What the payments were for

  • Food & beverage$71696%
  • Entertainment$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746 in reported general payments places this provider in the 45th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$102,264
Medicare patients
580
Services billed
7,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost182$50,814
RestasisCyclosporine41$30,554
XiidraLifitegrast19$20,914
VyzultaLatanoprostene Bunod44$17,398
SimbrinzaBrinzolamide/Brimonidine Tart50$11,332
Travoprost81$9,009
Brinzolamide26$5,543
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$4,394
RocklatanNetarsudil Mesylat/Latanoprost13$4,260
Latanoprost550$4,119
Alphagan PBrimonidine Tartrate17$4,042
RhopressaNetarsudil Mesylate12$3,922
Cyclosporine14$3,635
CombiganBrimonidine Tartrate/Timolol18$3,620
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat142$2,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$423$11,33250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Hazlehurst

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →